In an exclusive interview with 360Dx, Fluxergy CEO shares details of the company’s recently announced collaboration with NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Fluxergy is the first company to participate in the DDS program through NIAID, utilizing NIH-funded contractors to complete research projects on the company’s rapid Fluxergy Analyzer.
"This agreement with NIAID will allow us to accelerate progress toward commercialization of a full menu of easy-to-use, cost-effective, and lab-quality tests of the Fluxergy platform to address significant accessibility and affordability issues with point-of-care diagnostics available today," Fluxergy CEO Tej Patel said in a statement.
Read the full article on 360Dx here: https://www.360dx.com/molecular-diagnostics/through-agency-funded-contractors-niaid-aims-help-bring-infectious-disease
